Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.
OncLive TV
Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.
Advertisement
Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer
Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.
Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.
Dr. Peter Choyke, from the National Cancer Institute, Molecular Imaging Program, Discusses Current Molecular Imaging Research.
Advertisement
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.
Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.
Donna Berry, from the Dana-Farber Cancer Institute, Explains a Nurse-Led Education Program That Enhanced Oral Therapy Compliance.
Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.
Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.
Dr. Aleksandar Sekulic, from the Mayo Clinic in Arizona, on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma.
Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.
Dr. Hope Rugo, from the UCSF Helen Diller Family Comprehensive Cancer Center, Examines Angiogenesis Inhibition Trials in Advanced Breast Cancer.
Dr. Louis Weiner, from the Lombardi Comprehensive Cancer Center, Discusses the T-DM1 EMILIA Trial for HER2-Positive Breast Cancer.
Dr. Antoni Ribas, from UCLA Jonsson Comprehensive Cancer Center, on the Benefits of MAPK Inhibition With Dabrafenib and Trametinib
Dr. Ross Camidge, from the University of Colorado Cancer Center, Discusses Resequencing Lung Cancer
Suzanne Fuqua, PhD, from the Baylor College of Medicine, on the Utilization of Predictive Biomarkers
Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors
Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer
Robin McConnell, from John Theurer Cancer Center, Discusses Nutrition in Cancer Care
Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial
Paul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans
Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer
Dr. Edward Ambinder, from Mount Sinai School of Medicine, on the Potential Impact of using Apple's SIRI to aid Health Information Technology.
Dr. Michael Krychman, from he Southern California Center for Sexual Health and Survivorship Medicine, Discusses the Awareness of Sexual Health Concerns in Breast Cancer Patients.
Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer
Dr. Jeffrey Crawford from Duke University Medical Center Discusses Managing Cancer-Related Cachexia
Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Addresses the Importance of Palliative Care
Dr. Julie Gralow from the Seattle Cancer Care Alliance Discusses T-DM1-Induced Thrombocytopenia
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5